Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Starch × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Gastrointestinal 1

Conditions

Gastrointestinal Toxicity 1

Interventions

Paclitaxel 188 Carboplatin 157 pembrolizumab 114 Bevacizumab 84 liposomal doxorubicin 65 Gemcitabine 58 Cisplatin 54 olaparib 49 Topotecan 44 Nivolumab 32 niraparib 30 Doxorubicin 28 Cyclophosphamide 27 Docetaxel 26 Injections 21 Drug Therapy 20 1-dodecylpyridoxal 20 human papillomavirus vaccine, L1 type 16, 18 19 atezolizumab 18 Pemetrexed 18 lenvatinib 17 mirvetuximab soravtansine 16 fludarabine 16 Fulvestrant 16 avelumab 15 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15 durvalumab 14 Oxaliplatin 13 Irinotecan 13 Fluorouracil 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351089 2020-03-05

ProRad

Probi AB

Phase NA Terminated

GastrointestinalGynecologic

Gastrointestinal Toxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡